Literature DB >> 20578134

Syndromic mental retardation with thrombocytopenia due to 21q22.11q22.12 deletion: Report of three patients.

Eleni Katzaki1, Gilles Morin, Marzia Pollazzon, Filomena Tiziana Papa, Sabrina Buoni, Joussef Hayek, Joris Andrieux, Laure Lecerf, Cornel Popovici, Aline Receveur, Michèle Mathieu-Dramard, Alessandra Renieri, Francesca Mari, Nicole Philip.   

Abstract

During the last few years, an increasing number of microdeletion/microduplication syndromes have been delineated. This rapid evolution is mainly due to the availability of microarray technology as a routine diagnostic tool. Microdeletions of the 21q22.11q22.12 region encompassing the RUNX1 gene have been reported in nine patients presenting with syndromic thrombocytopenia and mental retardation. RUNX1 gene is responsible for an autosomal dominant platelet disorder with predisposition to acute myelogenous leukemia. We report on three novel patients with an overlapping "de novo" interstitial deletion involving the band 21q22 characterized by array-CGH. All our patients presented with severe developmental delay, dysmorphic features, behavioral problems, and thrombocytopenia. Comparing the clinical features of our patients with the overlapping ones already reported two potential phenotypes related to 21q22 microdeletion including RUNX1 were highlighted: thrombocytopenia with +/- mild dysmorphic features and syndromic thrombocytopenia with growth and developmental delay. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20578134     DOI: 10.1002/ajmg.a.33478

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  10 in total

1.  Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency.

Authors:  Tim Ripperger; Marcel Tauscher; Detlef Haase; Frank Griesinger; Brigitte Schlegelberger; Doris Steinemann
Journal:  Haematologica       Date:  2011-08-31       Impact factor: 9.941

Review 2.  Familial myelodysplastic syndromes: a review of the literature.

Authors:  Elena Liew; Carolyn Owen
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

3.  De Novo Truncating Variants in SON Cause Intellectual Disability, Congenital Malformations, and Failure to Thrive.

Authors:  Mari J Tokita; Alicia A Braxton; Yunru Shao; Andrea M Lewis; Marie Vincent; Sébastien Küry; Thomas Besnard; Bertrand Isidor; Xénia Latypova; Stéphane Bézieau; Pengfei Liu; Connie S Motter; Catherine Ward Melver; Nathaniel H Robin; Elena M Infante; Marianne McGuire; Areeg El-Gharbawy; Rebecca O Littlejohn; Scott D McLean; Weimin Bi; Carlos A Bacino; Seema R Lalani; Daryl A Scott; Christine M Eng; Yaping Yang; Christian P Schaaf; Magdalena A Walkiewicz
Journal:  Am J Hum Genet       Date:  2016-08-18       Impact factor: 11.025

4.  Recognizing familial myeloid leukemia in adults.

Authors:  Eric M Nickels; Jesse Soodalter; Jane E Churpek; Lucy A Godley
Journal:  Ther Adv Hematol       Date:  2013-08

5.  Control of alternative splicing by forskolin through hnRNP K during neuronal differentiation.

Authors:  Wenguang Cao; Aleh Razanau; Dairong Feng; Vincent G Lobo; Jiuyong Xie
Journal:  Nucleic Acids Res       Date:  2012-06-08       Impact factor: 16.971

6.  Chromosome anomalies in bone marrow as primary cause of aplastic or hypoplastic conditions and peripheral cytopenia: disorders due to secondary impairment of RUNX1 and MPL genes.

Authors:  Cristina Marletta; Roberto Valli; Barbara Pressato; Lydia Mare; Giuseppe Montalbano; Giuseppe Menna; Giuseppe Loffredo; Maria Ester Bernardo; Luciana Vinti; Simona Ferrari; Alessandra Di Cesare-Merlone; Marco Zecca; Francesco Lo Curto; Franco Locatelli; Francesco Pasquali; Emanuela Maserati
Journal:  Mol Cytogenet       Date:  2012-10-01       Impact factor: 2.009

7.  Proximal 21q deletion as a result of a de novo unbalanced t(12;21) translocation in a patient with dysmorphic features, hepatomegaly, thick myocardium and delayed psychomotor development.

Authors:  Cathrine Jespersgaard; Ida N Damgaard; Nanna Cornelius; Iben Bache; Niels Knabe; Maria J Miranda; Zeynep Tümer
Journal:  Mol Cytogenet       Date:  2016-02-04       Impact factor: 2.009

8.  RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.

Authors:  Anna L Brown; Peer Arts; Catherine L Carmichael; Milena Babic; Julia Dobbins; Chan-Eng Chong; Andreas W Schreiber; Jinghua Feng; Kerry Phillips; Paul P S Wang; Thuong Ha; Claire C Homan; Sarah L King-Smith; Lesley Rawlings; Cassandra Vakulin; Andrew Dubowsky; Jessica Burdett; Sarah Moore; Grace McKavanagh; Denae Henry; Amanda Wells; Belinda Mercorella; Mario Nicola; Jeffrey Suttle; Ella Wilkins; Xiao-Chun Li; Joelle Michaud; Peter Brautigan; Ping Cannon; Meryl Altree; Louise Jaensch; Miriam Fine; Carolyn Butcher; Richard J D'Andrea; Ian D Lewis; Devendra K Hiwase; Elli Papaemmanuil; Marshall S Horwitz; Georges Natsoulis; Hugh Y Rienhoff; Nigel Patton; Sally Mapp; Rachel Susman; Susan Morgan; Julian Cooney; Mark Currie; Uday Popat; Tilmann Bochtler; Shai Izraeli; Kenneth Bradstock; Lucy A Godley; Alwin Krämer; Stefan Fröhling; Andrew H Wei; Cecily Forsyth; Helen Mar Fan; Nicola K Poplawski; Christopher N Hahn; Hamish S Scott
Journal:  Blood Adv       Date:  2020-03-24

9.  Modeling partial monosomy for human chromosome 21q11.2-q21.1 reveals haploinsufficient genes influencing behavior and fat deposition.

Authors:  Anna M Migdalska; Louise van der Weyden; Ozama Ismail; Jacqueline K White; Gabriela Sánchez-Andrade; Darren W Logan; Mark J Arends; David J Adams
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

10.  Genetic basis of myeloid transformation in familial platelet disorder/acute myeloid leukemia patients with haploinsufficient RUNX1 allele.

Authors:  M Sakurai; H Kasahara; K Yoshida; A Yoshimi; H Kunimoto; N Watanabe; Y Shiraishi; K Chiba; H Tanaka; Y Harada; H Harada; T Kawakita; M Kurokawa; S Miyano; S Takahashi; S Ogawa; S Okamoto; H Nakajima
Journal:  Blood Cancer J       Date:  2016-02-05       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.